Sutro Biopharma Doses First Patients in Phase 1 Trial of STRO-004 for TF-Expressing Solid Tumors
Sutro Biopharma Inc. has commenced a Phase 1 clinical trial for STRO-004, a TF-targeting antibody drug conjugate, in patients with advanced TF-expressing solid tumors. The trial will evaluate safety, pharmacokinetics, and preliminary anti-tumor activity across various cancer types. Initial data is expected by mid-2026. This announcement was originally published by Sutro Biopharma via GlobeNewswire.
Sutro Biopharma Inc. has announced the dosing of the first cohort of patients in its Phase 1 clinical trial evaluating STRO-004, a next-generation tissue factor (TF)-targeting antibody drug conjugate (ADC), in patients with advanced TF-expressing solid tumors. The open-label, multicenter trial will assess the safety, pharmacokinetics, and preliminary anti-tumor activity of STRO-004 in various cancer types, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and bladder cancer. Initial clinical data from the study are expected to be presented in mid-2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595561-en) on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
